{
Pfizer Inc.

Companies

}
endometriosis treatment market projected to reach 3.1 billion by 2034
The endometriosis treatment market is projected to grow from USD 1.4 billion in 2023 to USD 3.1 billion by 2034, driven by increasing awareness and advancements in treatment options. Key trends include the rise of non-hormonal therapies and personalized medicine, while challenges such as high costs and limited access persist, particularly in developing regions. The competitive landscape features major players like AbbVie and Pfizer, alongside emerging companies innovating to meet unmet needs.
openPR.com
United States Dollar AstraZeneca PLC AbbVie Inc. Bayer AG Johnson & Johnson Pfizer Inc. USA DEU AbbVie Inc. Bayer AG AstraZeneca Johnson & Johnson Pfizer Inc. Show more
Healthcare, Market Report
16:12 19.11.2024
pharmaceutical industry struggles to improve access to medicine in low-income countries
Pharmaceutical companies are increasingly focusing on access to medicines in low-income countries, with Novartis leading the way by integrating access plans into 96% of its late-stage drug projects. However, many companies still prioritize the US market, resulting in limited availability of essential medicines globally. Roche aims to double patient treatment numbers in low-income regions by 2026, yet significant gaps in transparency and patient reach persist across the industry.
SWI swissinfo.ch
Bristol-Myers Squibb Company GSK plc Hoffmann-La Roche AG AbbVie Inc. Sanofi Novo Nordisk A/S Novartis AG Johnson & Johnson Pfizer Inc. GBR CHE NLD Jayasree Iyer Sabastine Wakdok Show more
Healthcare, Market Report
14:30 19.11.2024
global hashimoto thyroiditis market projected to reach 12.6 billion by 2033
The global Hashimoto"s thyroiditis market is projected to grow from $8.3 billion in 2023 to $12.6 billion by 2033, with a CAGR of 4.26%. North America is expected to dominate the market, while Asia-Pacific will experience the fastest growth due to rising healthcare awareness and improved infrastructure. The tablet segment will hold the largest market share, driven by convenience and patient compliance.
Spherical Insights
United States Dollar Amgen Inc. Merck & Co., Inc. Novartis AG Sanofi Mylan N.V. Teva Pharmaceutical Industries Ltd. Bristol-Myers Squibb Company Takeda Pharmaceuticals Limited Company Bayer AG Pfizer Inc. Roche Holding AG AbbVie Inc. AstraZeneca PLC Eli Lilly and Company Glaxosmithkline plc ARG GBR FRA ITA KOR ZAF MEX USA BRA ESP SAU CAN QAT ARE JPN AUS DEU CHN RUS IND Pfizer Inc. AbbVie Inc. Mylan N.V. Inc. Merck & Co GlaxoSmithKline plc Show more
Healthcare, Market Report
04:38 19.11.2024
regenerative medicine market projected to reach 349 billion by 2033
The global regenerative medicine market is projected to grow from USD 31.90 billion in 2023 to USD 349.93 billion by 2033, with a CAGR of 27.06%. Cell therapy leads in market share, while musculoskeletal conditions are expected to grow the fastest. North America dominates the market due to advanced healthcare infrastructure and increased funding for research and development.
Spherical Insights
United States Dollar Novartis AG Hoffmann-La Roche AG Johnson & Johnson ReNeuron Pfizer Inc. USA GBR AUS KOR CHN IND BRA ITA MEX FRA ESP ZAF JPN DEU ARE CAN Dr. Samuel Lynch Samuel Lynch Pfizer Lynch Johnson & Johnson Show more
Healthcare, Market Report
04:37 19.11.2024
global patient-centric healthcare applications market projected to reach 58.72 billion by 2033
The global patient-centric healthcare applications market is projected to grow from $11.90 billion in 2023 to $58.72 billion by 2033, with a CAGR of 17.31%. North America is expected to dominate the market, while the Asia-Pacific region will experience the fastest growth. Key drivers include increased patient convenience and the rapid expansion of telemedicine, despite challenges related to security and privacy concerns.
Spherical Insights
Siemens Healthineers AG Merck & Co., Inc. Pfizer Inc. Koninklijke Philips N.V. Boston Scientific Society USA Show more
Healthcare, Market Report
04:26 19.11.2024
ynthetic lethality drugs market projected to reach 5.3 billion by 2033
The global market for synthetic lethality drugs and targets is projected to grow from $1.3 billion in 2023 to over $5.3 billion by 2033, with a CAGR of 15.09%. North America is expected to dominate the market due to advances in genetic science and rising cancer rates, while the Asia-Pacific region is anticipated to experience the fastest growth. Key players include Pfizer, AbbVie, and AstraZeneca, with increasing investments in biotechnology and personalized medicine driving innovation in cancer treatment.
Spherical Insights
GlaxoSmithKline AbbVie Inc. Pfizer Inc. AstraZeneca CAN GBR FRA ARE ITA JPN KOR DEU MEX CHN ZAF USA BRA ESP IND Show more
Healthcare, Market Report
03:52 19.11.2024
impact of robert f kennedy jr on us healthcare sector uncertainty
Robert F. Kennedy Jr."s nomination as secretary of health has caused healthcare stocks to drop, particularly affecting vaccine manufacturers like Moderna and Pfizer. Analysts express uncertainty about his potential impact on the sector, especially regarding vaccine policies and obesity treatments, while noting that large-cap stocks may have room for future growth. Kennedy"s views on drug pricing and oversight of Medicare and Medicaid could also reshape negotiations with pharmaceutical companies.
Yahoo Finance
Novo Nordisk A/S Moderna, Inc. Eli Lilly and Company Pfizer Inc. USA Elon Musk Vivek Ramaswamy Donald Trump Robert Kennedy Jr. Show more
Regulatory & Legal, Market Report
19:27 18.11.2024
global consumer health market projected to reach over 713 billion by 2033
The global consumer healthcare market is segmented by product types, including OTC pharmaceuticals, personal care products, and dietary supplements, with offline distribution channels expected to dominate. North America is projected to lead the market due to rising awareness of wellness products, while Asia Pacific is anticipated to grow rapidly, driven by increasing disposable incomes and a large elderly population. Key players include Johnson & Johnson, Procter and Gamble, and Pfizer, among others, with ongoing developments enhancing market dynamics.
Spherical Insights
United States Dollar Johnson & Johnson Colgate-Palmolive Company Bayer AG Merck & Co., Inc. Boehringer Ingelheim GmbH Nestlé S.A. Mylan N.V. Reckitt Benckiser Group plc Novartis International AG Glaxosmithkline plc Eli Lilly and Company Perrigo Company plc Sanofi Teva Pharmaceutical Industries Ltd. Abbott Laboratories Pfizer Inc. Procter and Gamble ESP IND QAT GBR JPN KOR AUS ARE CHN DEU USA BRA RUS MEX CAN ARG ITA SAU ZAF Brian Johnson Mylan Nv Show more
Healthcare, Market Report
18:35 18.11.2024
political turmoil impacts bio pharmaceutical stocks with long term potential
Shares of BioNTech, Moderna, and Pfizer are under pressure following Donald Trump's announcement to appoint anti-vaccine advocate Robert F. Kennedy Jr. as Secretary of Health and Human Services, raising concerns over increased regulation and reduced government support.Despite short-term turbulence, BioNTech's acquisition of Biotheus and ongoing cancer research projects signal long-term potential. Pfizer is also focusing on gene therapy and oncology, presenting opportunities for investors willing to navigate the current volatility.
finanznachrichten.de
United States Dollar Euro BioNTech SE Pfizer Inc. USA Donald Trump Robert F. Kennedy Jr.
Healthcare, Market Report
10:46 18.11.2024
hope amid chaos trump musk and kennedy's controversial government impact
The new U.S. administration, featuring Trump, Musk, and Kennedy Jr., raises concerns due to their controversial views on global warming, vaccinations, and Russia. However, their actions suggest a less dire outcome, as Trump’s presidency saw fewer wars compared to his predecessor, and Musk's innovations have advanced environmental alternatives. Kennedy's health initiatives also address significant public health issues, indicating potential positive impacts despite their rhetoric.
Tages-Anzeiger
Euro United States Dollar SpaceX Pfizer Inc. Moderna, Inc. Tesla, Inc. USA DEU RUS UKR Robert F. Kennedy Jr. Elon Musk Donald Trump Show more
Healthcare, News Article
08:01 17.11.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Market Sentiment Analysis Banking Regulations Central Bank Actions Corporate Responsibility & ESG Decentralized Finance (DeFi) Innovations Tokenomics and Crypto Economics Cryptocurrency & Blockchain Regulations Mergers & Acquisitions Cryptocurrency Developments Blockchain Technology Adoption Anti-Money Laundering (AML) Regulations Market Analysis and Predictions Cryptocurrency Regulations Emerging Startups SEC & Financial Compliance Inflation Rates & CPI Data Banking & Investment Regulations
Countries:
USA CHE GBR DEU ARE HKG AUS JPN IND CHN CAN SGP DNK AUT LIE KOR NGA FIN COL VGB
Companies:
Credit Suisse Real Estate Fund Siat Coinbase Global, Inc. BlackRock, Inc. Solana USD Ripples USD Ethereum USD Apple Inc. Tesla, Inc. Fidelity Contrafund Cardano USD NVIDIA Corporation Grayscale Litecoin Trust Chainlink USD Tether USDt CNY Google Inc. Amazon.com, Inc. MicroStrategy Inc Franklin Templeton - Franklin M End Federal Reserve USD MicroStrategy Incorporated
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Indian Rupee Canadian Dollar Mozambican Metical British Pound Sterling Norwegian Krone Mongolian Tögrög Colombian Peso Singapore Dollar
People:
Donald Trump Ali Martinez Elon Musk Karin Keller-Sutter Jerome Powell Ueli Maurer Michael J. Saylor Gary Gensler Thomas Jordan Colm Kelleher Alan Santana Paul Atkins Joe Rogan Martin Schlegel Isabelle Chassot Mario Nawfal Paolo Ardoino Sergio Ermotti Dana White Joe Biden

MachinaCore is a highly modular and scalable system that allows users to build custom widgets and tools tailored to their specific financial data needs, while seamlessly integrating with other MachinaLabs products, like Machinary, MachinaAI Modules and MachinaTrader.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.